Wednesday, October 22, 2025

Psyched Wellness Moves To Next Stage Of Pre-Clinical Trials With Mushroom Extract

Psyched Wellness (CSE: PSYC) continues to execute on its strategy as it pertains to the amanita muscaria mushroom. The company, through its contract research organization, KGK Science, has now begun the next pre-clinical trial study on its proprietary extract, referred to as AME-1.

The next round of pre-clinical trials focuses on the beneficial or adverse health extracts of the compound, with the trial referred to as a conditioned placement preference study. The study itself reportedly works by comparing characteristics of the association of the extract in an environment, to the association in another environment without the extract.

Effectively, the study will look into whether the compound developed by Psyched has any abuse potential. The trial is a means of determining whether psychological or physical dependence of the substance can be formed around the extract.

“In conjunction with the other studies the Company is conducting, this trial will bolster Psyched’s toxicological assessment of AME-1 and provide critical knowledge of any behavioral and neurological functional changes in a scientific setting. This is another key step in determining a safe dose of AME-1 for human consumption and moves Psyched closer to being able to bring our Amanita-based CPG products to market,” commented David Shisel, COO of Psyched Wellness.

Psyched Wellness last traded at $0.135 on the CSE.


FULL DISCLOSURE: Psyched Wellness is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Psyched Wellness on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

When 4% of Global Copper Disappears Overnight | David Gower – Emerita Resources

Mining M&A: Gold X2 Acquires Kesselrun Resources

They Said Oil Was Dead. They Were Wrong. | Michael Judson – Record Resources

Recommended

Steadright Enters MOU To Acquire Historic Goundafa Polymetallic Mine In Morocco

Military Seizes Power in Madagascar After President Flees

Related News

Psyched Wellness Files Patent Application For Proprietary AME-1 Extraction Process

Psyched Wellness (CSE: PSYC) has begun the process of protecting its intellectual property. The firm...

Wednesday, March 17, 2021, 07:32:20 AM

Psyched Wellness To Conduct Stability Tests On Proprietary Mushroom Extract

Psyched Wellness (CSE: PSYC) is progressing with the development of its flagship product, an extract...

Monday, July 26, 2021, 09:28:00 AM

David Nutt: Amanita Muscaria Due For More Research – The Daily Dive

Today on the Daily Dive, our host Cassandra Leah sits down with Dr David Nutt,...

Wednesday, March 10, 2021, 01:30:00 PM

Psyched Wellness Sees Positive Results From Amanita Muscaria Toxicology Report

Psyched Wellness (CSE: PSYC) has completed its toxicology assessment on that of Amanita Muscaria, the...

Monday, December 7, 2020, 07:56:50 AM

Daily Dive: Shroom Stocks About To Fly? With Jeff Stevens, CEO Of Psyched Wellness

Today on The Daily Dive we have Jeff Stevens, CEO of Psyched Wellness (CSE: PSYC)....

Monday, November 9, 2020, 01:00:00 PM